Q-omics provides the consensus-scored ALYREF profile across patient tissues and cancer cell-line models. ALYREF expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ALYREF is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ALYREF protein abundance shows 26,367 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, HNSC, and GBM as cancer lineages where ALYREF shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALYREF — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALYREF survival associations across molecular data types. ALYREF RNA expression shows survival associations in the most cancer types (29), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALYREF RNA expression–survival associations across cancer types. High ALYREF expression shows unfavorable associations in KIRP, ACC, LIHC, MESO, UVM and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ALYREF RNA expression.
This table summarizes ALYREF tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ALYREF. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALYREF shows higher tumor expression in HNSC, COAD, KIRP, BLCA, LUAD and LIHC. The HNSC box plot shows higher ALYREF RNA expression in tumor versus normal tissue (log2 FC = +1.256, t-test p < 0.001).
This table shows molecular features associated with ALYREF in patient tissues and cancer cell lines. In patient samples, ALYREF shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ALYREF RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
